Etelcalcetide for children with dialysis-related overactive parathyroid hormone
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies etelcalcetide in children who have chronic kidney disease and too much parathyroid hormone while on hemodialysis. It aims to safely lower the hormone levels and help manage related bone/mineral problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 28 days to under 18 years
- Be on hemodialysis for kidney disease and have secondary hyperparathyroidism confirmed by lab tests
- Have very high parathyroid hormone (two blood tests on separate days) above 300 pg/mL
- Meet calcium requirements from central lab (higher threshold for babies under 2 years)
- Have dialysis solution calcium at or above a set minimum level for at least 4 weeks
- Be able to stay on a stable dosing plan for certain vitamin D, phosphate binders, or calcium supplements before screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests etelcalcetide to lower a hormone called parathyroid hormone (PTH) in children who have kidney disease and secondary hyperparathyroidism while on hemodialysis. It may help control bone/mineral problems, but the study also checks heart rhythm safety and medication stability.
This study tests a new extended-release capsule (CTAP101) for children aged 8 to under 18 with moderate to severe chronic kidney disease (CKD). The goal is to see how the drug works in the body, if it's safe, and if it can help control mineral and hormone levels that are often out of balance in CKD.
This study watches how well the drug Pacitol Inj. works and how safe it is in people on dialysis who have overactive parathyroid glands caused by kidney disease. It follows patients who are already prescribed this drug by their doctor.
This study tests a medicine called etelcalcetide to see if it can protect vitamin K activity in people with kidney disease and overactive parathyroid glands who are on dialysis. It aims to slow down calcium buildup in blood vessels and reduce heart valve problems.
This trial tests a new medicine called MT1013 for people with secondary hyperparathyroidism who are on dialysis. It may help control high parathyroid hormone levels when current treatments are not enough.
This study tests a new injectable medicine called MT1013 for people with secondary hyperparathyroidism who are on regular kidney dialysis. It aims to see if MT1013 can help control high parathyroid hormone levels safely.
Hear when a new Secondary Hyperparathyroidism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.